Skip to main content
. 2020 Apr 9;30(7):903–915. doi: 10.1136/ijgc-2020-001288

Figure 2.

Figure 2

Criteria that may help clinicians in poly (ADP-ribose) inhibitor (PARPi) treatment selection for ovarian cancer. EORTC, European Organization for Research and Treatment of Cancer; FACIT, Functional Assessment of Chronic Illness Therapy; HR Qol, health-related quality of life; ICER, incremental cost-effectiveness ratio; Pfs2, progression after the next line of therapy; PRO: patient-reported outcomes; QALY, quality-adjusted life-year; TFST, time to first subsequent therapy; TSST, time to second subsequent therapy; WTP, willingness to pay.